Zentalis Pharmaceuticals, Inc. · NASDAQ:ZNTL

Zentalis Pharmaceuticals — Investor Presentation (August 2026)

29 slides from Zentalis Pharmaceuticals's investor presentation, August 2026

  1. Slide 1: Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care

    Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care Corporate Presentation | August 2026 Nasdaq: ZNTL

  2. Slide 2: Forward Looking Statements and Disclaimer

    Forward Looking Statements and Disclaimer Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securiti

  3. Slide 3: A Focused Strategy to Address Critical Unmet Need in Ovarian Cancer and Beyond

    A Focused Strategy to Address Critical Unmet Need in Ovarian Cancer and Beyond Addressing ~20,000 Cyclin E1-positive PROC patients^ with no specifically targeted treatment options Investigational first-in-class WEE1 inhibitor, azenosertib demonstrates compelling clinical profile as a potential oral,

  4. Slide 4: Strong Execution Drives Momentum Towards Key Value Inflection Points

    Strong Execution Drives Momentum Towards Key Value Inflection Points 1H 2027 2H 2026 Anticipated DENALI Part 2 2H 2025 1H 2026 topline readout (all cohorts); Part 2 designed as a Selected 400mg QD 5:2 Completed DENALI Part registration intended, Completed enrollment in as the monotherapy dose 2a & b

  5. Slide 5: ~50% of PROC Patients Are Cyclin E1-Positive With No Approved, Specifically Targeted Therapy

    ~50% of PROC Patients Are Cyclin E1-Positive With No Approved, Specifically Targeted Therapy The Unmet Need: • ~20,000 patients with Cyclin E1-positive PROC2 • Standard-of-care single-agent chemotherapy delivers only 4-13% ORR and 3-4 months PFS3 with high patient burden: PROC • Due to safety and to

  6. Slide 6: Robust Clinical Foundation Supports Azenosertib as Potential First-in-Class WEE1 Inhibitor

    Robust Clinical Foundation Supports Azenosertib as Potential First-in-Class WEE1 Inhibitor for Cyclin E1-Positive PROC Class-leading Clinical Experience Optimized Dose & Schedule Compelling Clinical Profile • 1,000+ patients treated across • 400mg QD 5:2 selected based on • >30% ORR and ~6 month DOR

  7. Slide 7: DENALI: Registration-Intended Study in Cyclin E1-Positive PROC for Accelerated Approval

    DENALI: Phase 2 Registration-Intended Study in Cyclin E1-Positive PROC for Accelerated Approval DENALI PART 2 FOR POTENTIAL ACCELERATED APPROVAL (N= ~140 at selected dose) Key Eligibility Part 2a Part 2b Dose Confirmation Dose Expansion Dose ✓ Platinum-resistant Selected ovarian cancer Seamless Enro

  8. Slide 8: ASPENOVA: Phase 3 Confirmatory Study in Cyclin E1-Positive PROC for Full Approval

    ASPENOVA: Phase 3 Confirmatory Study in Cyclin E1-Positive PROC for Full Approval ASPENOVA RANDOMIZED TRIAL INTENDED FOR FULL APPROVAL (FDA Aligned, N= ~420) Key Eligibility Primary Azenosertib Endpoint ✓ Platinum-resistant Prescreening / Tissue Consent ovarian cancer 400mg QD 5:2 (N = ~210) PFS ✓ C

  9. Slide 9: Focused Pipeline with Registration-Intended Cyclin E1-Positive PROC Trials

    Focused Pipeline with Registration-Intended Cyclin E1-Positive PROC Trials Potential for Franchise Expansion in Earlier Lines of Ovarian Cancer and Other Tumor Types TRIAL DEVELOPMENT APPROACH PHASE 1 PHASE 2 PHASE 3 STATUS Cyclin E1-Positive PROC Monotherapy (lead indication) DENALI Part 1b In Long

  10. Slide 10: Cyclin E1-Positive PROC Patients Face Poor Prognosis with No Specifically Targeted Treatment Options

    Cyclin E1-Positive PROC Patients Face Poor Prognosis with No Specifically Targeted Treatment Options 10 Abbreviations: PROC = platinum-resistant ovarian cancer

  11. Slide 11: Cyclin E1 Protein Overexpression is the Key Biomarker Identifying PROC Patients

    Cyclin E1 Protein Overexpression is the Key Biomarker Identifying PROC Patients Who may Benefit from Azenosertib Monotherapy All PROC Patients Should Be Screened by IHC Regardless of CCNE1 Gene Amplification Status CCNE1 Amplified CCNE1 Non-Amplified (~20% of PROC) (~80% of PROC) ~15% ~50% of PROC p

  12. Slide 12: Cyclin E1-Positive Patients Experience Significantly Worse Outcomes with Current Treatments

    RWD, AACR 2026 Cyclin E1-Positive Patients Experience Significantly Worse Outcomes with Current Treatments Prior Tx Data from • Cyclin E1-positive ovarian cancer Tempus Lens Real Patients Enrolled in patients show consistently poor World Data^† Azenosertib (N=193) Clinical Trials^ outcomes across tw

  13. Slide 13: Standard-of-Care Single-Agent Chemotherapy Delivers Limited Benefits to PROC Patients

    Standard-of-Care* Single-Agent Chemotherapy Delivers Limited Benefits to PROC Patients Study Study Population Chemotherapy Arm ORR, % mPFS, mo mOS, mo JAVELIN Ovarian 2001 ≤3 priors, 75% PROC and 25% PLD 4 3.5 15.7 (n=190) Platinum refractory (28% prior bev) FORWARD I re-read2 PROC 1–3 priors high F

  14. Slide 14: Azenosertib May Address Critical Gap in Cyclin E1-Positive PROC Treatment Landscape

    Azenosertib May Address Critical Gap in Cyclin E1-Positive PROC Treatment Landscape* No approved therapies specifically for Cyclin E1+ PROC presents opportunity for azenosertib as potentially first, oral, non-chemotherapy for ~50% of PROC patients Untreated Stage III/IV First Line First Line Second

  15. Slide 15: Compelling Clinical Profile Across Multiple Studies Supports Cyclin E1-Positive PROC Registration Strategy

    Compelling Clinical Profile Across Multiple Studies Supports Cyclin E1-Positive PROC Registration Strategy 15 Abbreviations: PROC = platinum-resistant ovarian cancer

  16. Slide 16: Azenosertib: A Differentiated, Potentially First-in-Class WEE1 Inhibitor

    Azenosertib: A Differentiated, Potentially First-in-Class WEE1 Inhibitor Normal Cell Cycle Regulation Cancer Cell and Azenosertib • CDKs and their cyclin binding partners promote progression through • Cyclin E1 overexpression increases CDK2 activity and accelerates G1-S the cell cycle transition, re

  17. Slide 17: Integrated Data Across Multiple Early Clinical Studies Demonstrate Compelling Benefit-Risk Profile

    Integrated Analysis Integrated Data Across Multiple Early Clinical Studies Demonstrate Compelling Benefit-Risk Profile for Azenosertib Monotherapy in PROC Learnings from ZN-c3-001, MAMMOTH, and DENALI Part 1b Inform Registration Strategy in Cyclin E1+ PROC ZN-c3-001 MAMMOTH DENALI Part 1b First-in-h

  18. Slide 18: 400mg QD 5:2 Shows >30% ORR and ~6 Month Duration in Cyclin E1-Positive PROC

    Integrated Analysis 400mg QD 5:2 Shows >30% ORR and ~6 Month Duration in Cyclin E1-Positive PROC PROC, Cyclin E1+ 100 — 300 mg 5:2 400 mg 5:2 300mg 5:2 400mg 5:2 (001, MAMMOTH, DENALI Part 1b) (N=18) (N=68) ORR in response evaluable* 22.2% (4/18) 33.8% (23/68) 80 — (95% CI) (6.4 - 47.6) (22.8 - 46.3

  19. Slide 19: Safety and Tolerability at 300mg and 400mg QD 5:2 Broadly Comparable

    Integrated Analysis Safety and Tolerability at 300mg and 400mg QD 5:2 Broadly Comparable Monotherapy Safety Profiles in PROC Patients from Integrated Analysis (001, MAMMOTH, DENALI Part 1b) 300mg (N=38) 400mg (N=165) 300mg 400mg Treatment-related All Grade Grade 3+ All Grade Grade 3+ (N=38) (N=165)

  20. Slide 20: DENALI Part 1b Patient Characteristics: Heavily Pre-Treated PROC Population

    DENALI Part 1b, SGO 2025 DENALI Part 1b Patient Characteristics: Heavily Pre-Treated PROC Population ~50% of Patients Identified with Cyclin E1 Overexpression per IHC Retrospectively Characteristicsa (N=102) Characteristicsa (N=102) Median age (range), years 66 (34-82) Prior therapy, n (%) Race, n (

  21. Slide 21: DENALI Part 1b Demonstrated Cyclin E1 as Predictive Biomarker for Response to Azenosertib

    DENALI Part 1b, SGO 2025 DENALI Part 1b Demonstrated Cyclin E1 as Predictive Biomarker for Response to Azenosertib 34.9% ORR in Cyclin E1-Positive Patients vs 20.4% in All-Comers All treated patientsa (N=102) Biomarker positive: Cyclin E1 IHCb (n=48) ORR in response-evaluable patients ORR in respons

  22. Slide 22: Durable Responses Observed in Cyclin E1-Positive PROC Patients

    DENALI Part 1b, SGO 2025 Durable Responses Observed in Cyclin E1-Positive PROC Patients Cyclin E1+ (N=48) • Durable responses observed regardless of mDOR 6.3 monthsa CCNE1 amplification (95% CI, 2.7 - NE) status, reinforcing Cyclin mPFS 4.1 months E1 IHC as the predictive biomarker Patients (95% CI,

  23. Slide 23: DENALI Part 1b Safety and Tolerability Summary

    DENALI Part 1b, SGO 2025 DENALI Part 1b Safety and Tolerability Summary TRAEs occurring in ≥10% of patientsa TRAEs, n (%) Hematological Thrombocytopenia Leading to dose reduction 44 (43.1) 12 23 Grade ≥3 Anemia 11 18 Grades 1-2 Leading to dose interruption 59 (57.8) Neutropenia 11 5 Gastrointestinal

  24. Slide 24: Building Azenosertib Franchise in Ovarian Cancer and Beyond

    Building Azenosertib Franchise in Ovarian Cancer and Beyond 24

  25. Slide 25: MUIR: Ongoing Phase 1b, Part 2 Study of Azenosertib in Combination with Bevacizumab

    MUIR: Ongoing Phase 1b, Part 2 Study of Azenosertib in Combination with Bevacizumab Focused on Platinum Sensitive Ovarian Cancer Part 1 Part 2 Key Eligibility Azenosertib + Chemo Combo in Azenosertib + Bevacizumab PROC as 1L/2L PSOC Maintenance Therapy ✓ Advanced ovarian, Azenosertib + Dose Escalati

  26. Slide 26: Azenosertib Combinations Demonstrate Compelling Activity in Preclinical ADC-Resistant TNBC Models

    Preclinical TNBC, Azenosertib Combinations Demonstrate Compelling Activity in AACR 2026 Preclinical ADC-Resistant Triple-Negative Breast Cancer Models TNBC Exhibits High Cyclin E1 Expression and Sensitivity to WEE1 Inhibition Azenosertib + EV Induces Complete Responses • As ADCs advance toward first

  27. Slide 27: Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care

    Pioneering WEE1 Inhibition to Deliver More Convenient, Targeted Cancer Care for Patients with Cyclin E1-Positive Ovarian Cancer and Beyond 27

  28. Slide 28: Our Mission: Delivering a More Convenient, Targeted Approach to Cancer Care

    Our Mission: Delivering a More Convenient, Targeted Approach to Cancer Care • First investigational oral, non-chemo targeted therapy for Cyclin E1-positive PROC patients with no specifically targeted treatment options • Compelling azenosertib clinical profile: >30% ORR and ~6 month mDOR* in biomarke

  29. Slide 29: Julie Eastland, Haibo Wang, Aron Feingold

    Julie Eastland Haibo Wang Aron Feingold Chief Executive Officer Chief Business Officer VP, IR and Corporate Communications jeastland@zentalis.com hwang@zentalis.com afeingold@zentalis.com

Zentalis Pharmaceuticals — Investor Presentation (August 2026) on 6ix